NEW YORK (GenomeWeb) – Opko Health reported after the close of the market Monday that its third quarter revenues jumped 108 percent compared to Q3 2015, driven primarily by revenues from clinical lab BioReference Laboratories, which it acquired in August 2015.

For the three-month period ended Sept. 30, Opko's revenues rose to $298.0 million from $143.0 million a year ago, missing Wall Street analysts' consensus estimate for revenues of $322.0 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.